( July 27, 2026, 3:22 PM EDT) -- WASHINGTON, D.C. — After a June opinion in which a Federal Circuit U.S. Court of Appeals panel affirmed a Massachusetts federal judge’s finding that a biopharmaceutical company’s patent claims were invalid as anticipated by a public disclosure of a chemical compound central to the patent, the patent holder has filed a petition for panel rehearing or rehearing en banc, arguing that the panel’s opinion creates a new and unprecedented requirement for an in haec verba disclosure to satisfy the written description requirement....